Le Lézard
Classified in: Health

DailyBreath Among 1 of 3 in Virginia Spotlighted in #WeArePlay Campaign

Spotlights the Inspiration for the Passion that Drove the Creation of DailyBreath, which Aims to Help Avoid Potentially Preventable Asthma Attacks!

CLIFTON, Va., July 07, 2022 /PRNewswire-PRWeb/ -- DailyBreath, LLC, a cloud-based SAAS company delivering personalized environmental insights for better asthma outcomes, announces its mobile app, DailyBreath, has been spotlighted in the #WeArePlay campaign featuring stories of people building apps and games businesses on Google Play. "I was pleased that DailyBreath was selected to be featured in this campaign as it describes how my passion for its creation was inspired by a real story of tragedy from a potentially preventable asthma attack." said Eric Klos, CEO. The complete DailyBreath #WeArePlay story is available online at http://g.co/play/weareplay-usa. DailyBreath was one of only 3 to be featured for the state of Virginia in the United States portion of this worldwide campaign. The mobile app, DailyBreath, is available via Google Play for free to a worldwide population of over 330 million people with asthma.

With 30,000 asthma attacks, leading to 5000 ER visits, resulting in 1000 hospital stays in the US every day, and with climate change worsening environmental impacts on health, now is the time to tackle the problem upstream before respiratory distress occurs. Experiencing symptoms because of exposure triggers seems to be an accepted norm, yet by using DailyBreath, asthma patients may potentially prevent the symptoms march towards respiratory distress. In the #WeArePlay featured story, Eric is quoted, "Our goal is to empower people to respond to what triggers their symptoms. We want to tell people what their risk is and give them tools to make sure they don't have an asthma attack." In the featured story, Eric further notes," Google Play seems to be very interested in start-ups. The developer platform is easy to use and there is a lot of functionality in it."

Registration is required for the free version of DailyBreath for members to begin recording symptoms and developing your personalized risk index. DailyBreath Plus, an upgrade for .99 annually, includes features to customize and personalize your use of the app. DailyBreath is also the only asthma app tracking wildfire smoke with its in-app purchase, DailyBreath SHOW, for .99 annually, which shows an overlay of where smoke is present across the U.S (going globally in the future) and allows for the recording of symptoms that may be associated with your location within the smoke dispersion path.

DailyBreath aims to help those with asthma experience, individually and collectively, less symptoms, less attacks, less suffering, less ER visits and hospital stays, an overall better quality of life, and potentially, save lives. Its mission is to help everyone breathe easier one symptom at a time.

About DailyBreath

DailyBreath is an environmental health intelligence and asthma wellness platform. The DailyBreath app is available via Google Play or in the App Store. DailyBreath, LLC is a cloud based SAAS company delivering environmental insights for better asthma outcomes. Helping Everyone Breathe Easier One Symptom at a Time! For more information visit http://www.dailybreathforecast.com

Media Contact

Eric Klos, DailyBreath, +1 (703) 403-9618, [email protected]



SOURCE DailyBreath

These press releases may also interest you

at 20:30
On August 1, 2022, U.S. time, ImmVira's brand new oncolytic herpes simplex virus ("oHSV") product MVR-C5252 targeting Malignant Glioma has obtained Orphan Drug Designation ("ODD") from U.S. Food and Drug Administration ("FDA"). Malignant glioma has...

at 20:10
--ASC61 is an in-house developed oral PD-L1 small molecule inhibitor prodrug that showed significant antitumor efficacy in preclinical studies as a single agent in multiple animal models --ASC61-A treatment induced secretion of IFN? in a...

at 20:05
GEMSTONE-301 study result was presented at IASLC 2022 World Conference on Lung Cancer. In addition, the leading Principal Investigator Professor Yi-Long Wu was invited to highlight key data in a press conferenceIn the final progression-free survival...

at 20:00
NaoTrac, the CE-certified neurosurgical navigation robot, achieved approval from Taiwan's Food and Drug Administration (TFDA) in July 2022, and is planned for submission to the FDA (U.S. Food and Drug Administration) for clearance by the end of 2022....

at 20:00
Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces the appointment of...

at 20:00
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major...

News published on 7 july 2022 at 06:00 and distributed by: